Dublin, Sept. 08, 2017 -- The "China In-Vitro Diagnostics (IVD) Market, Forecast, Companies Analysis, and Registration Rules" report has been added to Research and Markets' offering.
China In-vitro diagnostics market is expected to be triple its market size by the end of 2022 from its market size in 2016. China In-Vitro Diagnostics sector is expected to grow with a double digit CAGR of 19.01% in future. With such a huge growth rate China is poised to become the world's largest In-vitro Diagnostics (IVD) Market in the next few years for both domestic and foreign IVD products. The In-Vitro Diagnostics (IVD) Market in China has been growing rapidly over the past few years and is expected to grow steadily in the coming future, with major growth potential in segments such as contagious disease testing, chronic disease testing and diagnosis in early stages of disease.
Immunoassay has the highest market share in China IVD market, but after 2018 its market share will decline. China Microbiology Market has grown approximately 4 times in 2016 compared to its market value in 2007. China Molecular Testing Market is expected to grow almost five times in future from its present market. Contribution of Point of Care Testing (POCT) market is low compared to Hematology Market, Coagulation Market and Self Monitoring of Blood Glucose (SMBG) Market. Other segments such as Molecular testing, Clinical Chemistry and Microbiology are poised to be remarkable expansion in the near future. Roche is the leading company in the China IVD market.
Some of the key factors driving the growth of China IVD market are the rising incidences of chronic lifestyle diseases, public health awareness, growing aging population, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high-end products and an increase in the number of hospitals and independent clinical laboratories.
China In-Vitro Diagnostics (IVD) Market, Forecast, Companies Analysis, Registration Rules is the 5th edition report on In-Vitro Diagnostics. This presents a detailed account of In-Vitro Diagnostics Market, its 8 Segments Market, Companies In-Vitro Diagnostics Sales in China, Registration of In-Vitro Diagnostics in China.
This 101 Page report with 36 Figures and 2 Tables studies the China IVD market from 6 view points:
1) Market and Forecast
2) Segment Wise Market & Forecast
3) Development Environment & Regulatory Status in China IVD market
4) Company Wise IVD Sales & Forecast
5) Growth Drivers for China In-Vitro Diagnostics
6) Challenges for China In-Vitro Diagnostics
China IVD Market - Segment Analysis (2007 - 2022):
1. Clinical Chemistry Market & Forecast
2. Immunoassay Market & Forecast
3. Hematology Market & Forecast
4. Coagulation Market & Forecast
5. Microbiology Market & Forecast
6. Molecular Testing Market & Forecast
7. Self Monitoring of Blood Glucose (SMBG) Market & Forecast
8. Point of Care Testing (POCT) Market & Forecast
China IVD - Companies Sales Analysis (2011 - 2022):
1. Roche Diagnostics
2. Sysmex Corporation
3. Mindray Medical International Limited
4. Shanghai Kehua Bio-Engineering Co. Ltd.
5. Abbott Laboratories
6. Others
Profiles of Private Clinical Labs and Diagnostic Services Companies in China
- Zhejiang Di'an Diagnostics Technology Co., Ltd
- ADICON Clinical Laboratories
- Guangzhou Kingmed Diagnostics Center Co. Ltd.
- Kindstar Global (Privately held)
- BGI-Shenzhen (Privately held)
- OriGene Technologies (Privately held)
For more information about this report visit https://www.researchandmarkets.com/research/cxrf7p/china_invitro
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: In Vitro Diagnostics


Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 



